-
Feb 26, 2021 08:10 PM IST The construction sector, which contributes 9 percent to India’s GDP, is back with a bang. The high leverage business saw a strong recovery in execution and growth on a year-on-year basis with companies reported double-digit growth in profitability. With growth back on track which are the stocks to hedge your bets? Watch the video to find out.
-
Feb 26, 2021 10:55 AM IST While rural markets are stable, the resurgence in industrial activity and pent-up demand from tier 1 markets are driving the uptick in business volumes for Cera
-
Feb 26, 2021 10:49 AM IST We remain positive on our high conviction ideas -- companies with lower debt to equity and better execution capabilities -- such as KNR, PNC and HG Infra which we believe could take full advantage of the infra boom
-
Feb 25, 2021 11:57 AM IST Going by the management commentary and the allocations in the Union Budget for infrastructure and housing, FY22 could be a year of strong volume recovery for HeidelbergCement
-
Feb 25, 2021 10:47 AM IST Capex projects for Aarti Industries are on track and are backed by a budget of about Rs 1,000-1,200 crore per annum for the next 4-5 years
-
Feb 24, 2021 10:30 AM IST Investors need to focus on real economy facing capital intensive business to ride the next wave of secular wealth creation
-
Feb 23, 2021 07:36 PM IST For this company, unlike its peers, China remains a major export destination. As its IPO takes off today, should you give it a look?
-
Feb 23, 2021 12:32 PM IST The proposed reorganisation of the O2C business adds to the prospect of raising growth capital, which in turn will serve as a catalyst for the legacy growth engine of RIL
-
Feb 23, 2021 09:57 AM IST Coming to valuations, Heranba appears reasonably priced, given its return ratios and margin profile. The key aspect that differentiates is that China is a major export destination for the company.
-
Feb 22, 2021 11:23 AM IST In CY21, the industry participants expect volume to grow 15-17 per cent from a low base
-
Feb 22, 2021 10:42 AM IST Fermenta Biotech’s near-term growth for the Human Vitamin D3 volume is contingent on commissioning of the Dahej plant in the current quarter
-
Feb 19, 2021 10:44 AM IST Valuation at a discount to peers, but significant scope for margin improvement
-
Feb 19, 2021 10:33 AM IST The market cap of the Tata group’s listed companies has risen at a faster clip than the Nifty during Chandra’s stint. The dependence on TCS for profits continues, but customer-facing businesses have gained
-
Feb 19, 2021 09:55 AM IST -
Feb 18, 2021 11:36 AM IST While COVID-19 turned out to be a speed breaker for fast-growing life insurers, the structural growth story of the insurance sector remains intact
-
Feb 16, 2021 09:57 AM IST Amber is in a strong position to capitalise on growing demand for electronic components because of a host of factors
-
Feb 16, 2021 09:53 AM IST According to HEG management, the industry level inventory has swiftly normalised, which points to higher utilisation levels and pricing growth in electrodes in the near term
-
Feb 15, 2021 11:01 AM IST NOCIL has set its growth guidance of an 8-10 percent increase in FY21
-
Feb 15, 2021 09:43 AM IST The 2021 outlook for cement demand appears encouraging due to higher government spending in infrastructure, but the sustained increase in pet coke and oil prices poses some risk to its margin profile
-
Feb 12, 2021 11:38 AM IST Berger’s share price has risen by 40 percent in the last 6 months beating the consumer index by a wide margin
-
Feb 12, 2021 11:06 AM IST In the injectables space, Aurobindo Pharma remains constructive and targets to almost double from current annual sales base of $380 million to $650-700 million in three years backed by new plants in the US and Vizag
-
Feb 11, 2021 01:28 PM IST The Street is cognizant of the exciting growth prospects of Dixon and, therefore, the stock has more than quadrupled in the past 12 months
-
Feb 11, 2021 11:26 AM IST Coming to near-term prospects, next year, Balaji Amines should benefit from additional volume from higher capacity, helped by firm demand in the pharma end-market
-
Feb 11, 2021 10:26 AM IST Earnings visibility is strong for Titan over the next one to two years
-
Feb 10, 2021 08:52 AM IST Given that the stock has been a big winner in recent months and has already doubled from Mar-20 lows, the valuations definitely appears optically expensive based on FY22/FY23 earnings.